Prot#AVL-292-003: Phase 1b, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects with Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulin

Project: Research project

Project Details

StatusFinished
Effective start/end date3/28/123/28/18

Funding

  • INC Research, LLC (AVL-292-003 // AVL-292-003)
  • Avila Therapeutics, Inc. (AVL-292-003 // AVL-292-003)